Shanafelt TD, Hanson C, Dewald GW, Witzig TE, LaPlant B, Abrahamzon J et al. Karyotype change on beaming in situ admixture assay is associated with abbreviate adaptation in patients with abiding lymphocytic leukemia and is accompanying to CD49d expression. J Clin Oncol 2008; 26: e5–e6.
Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L et al. Genomic aberrations and adaptation in abiding lymphocytic leukemia. N Engl J Med 2000; 343: 1910–1916.
Pettitt AR, Jackson R, Carruthers S, Dodd J, Dodd S, Oates M et al. Alemtuzumab in aggregate with methylprednisolone is a awful able consecration dieting for patients with abiding lymphocytic leukemia and abatement of TP53: Final after-effects of the National Blight Research Institute CLL206 Trial. J Clin Oncol 2012; 30: 1647–1655.
Spaner DE. Oral high-dose glucocorticoids and ofatumumab in fludarabine-resistant abiding lymphocytic leukemia. Leukemia 2012; 26: 1144–1145.
Stilgenbauer S, Zenz T, Winkler D, Buhler A, Schlenk RF, Groner S et al. Subcutaneous alemtuzumab in fludarabine-refractory abiding lymphocytic leukemia: analytic after-effects and anxiety brand analyses from the CLL2H abstraction of the German Abiding Lymphocytic Leukemia Abstraction Group. J Clin Oncol 2009; 27: 3994–4001.
Castro JE, James DF, Sandoval-Sus JD, Jain S, Bole J, Rassenti L et al. Rituximab in aggregate with high-dose methylprednisolone for the assay of abiding lymphocytic leukemia. Leukemia 2009; 23: 1779–1789.
Parikh SA, Keating MJ, O’Brien S, Wang X, Ferrajoli A, Faderl S et al. Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk abiding lymphocytic leukemia. Blood 2011; 118: 2062–2068.
Dreger P, Dohner H, Ritgen M, Bottcher S, Busch R, Dietrich S et al. Allogeneic axis corpuscle transplantation provides abiding ache ascendancy in poor-risk abiding lymphocytic leukemia: abiding analytic and MRD after-effects of the German CLL Abstraction Group CLL3X trial. Blood 2010; 116: 2438–2447.
Wang L, Lawrence MS, Wan Y, Stojanov P, Sougnez C, Stevenson K et al. SF3B1 and added aberant blight genes in abiding lymphocytic leukemia. N Engl J Med 2011; 365: 2497–2506.
Quesada V, Conde L, Villamor N, Ordonez GR, Jares P, Bassaganyas L et al. Exome sequencing identifies alternate mutations of the splicing agency SF3B1 gene in abiding lymphocytic leukemia. Nat Genet 2011; 44: 47–52.
Zhang X, Reis M, Khoriaty R, Li Y, Ouillette P, Samayoa J et al. Arrangement assay of 515 kinase genes in abiding lymphocytic leukemia. Leukemia 2011; 25: 1908–1910.
Ouillette P, Collins R, Shakhan S, Li J, Peres E, Kujawski L et al. Acquired genomic archetype cardinal aberrations and adaptation in abiding lymphocytic leukemia. Blood 2011; 118: 3051–3061.
Gunnarsson R, Mansouri L, Isaksson A, Goransson H, Cahill N, Jansson M et al. Array-based genomic screening at assay and during aftereffect in abiding lymphocytic leukemia. Haematologica 2011; 96: 1161–1169.
Gunnarsson R, Isaksson A, Mansouri M, Goransson H, Jansson M, Cahill N et al. Ample but not baby copy-number alterations associate to high-risk genomic aberrations and adaptation in abiding lymphocytic leukemia: a high-resolution genomic screening of anew diagnosed patients. Leukemia 2010; 24: 211–215.
Lehmann S, Ogawa S, Raynaud SD, Sanada M, Nannya Y, Ticchioni M et al. Atomic allelokaryotyping of early-stage, basic abiding lymphocytic leukemia. Blight 2008; 112: 1296–1305.
Pfeifer D, Pantic M, Skatulla I, Rawluk J, Kreutz C, Martens UM et al. Genome-wide assay of DNA archetype cardinal changes and LOH in CLL application high-density SNP arrays. Blood 2007; 109: 1202–1210.
Brown JR, Hanna M, Tesar B, Werner L, Pochet N, Asara JM et al. Integrative genomic assay implicates accretion of PIK3CA at 3q26 and MYC at 8q24 in abiding lymphocytic leukemia. Clin Blight Res 2012; 18: 3791–3802.
Grubor V, Krasnitz A, Troge JE, Meth JL, Lakshmi B, Kendall JT et al. Aberant genomic alterations and clonal change in abiding lymphocytic leukemia appear by representational oligonucleotide microarray assay (ROMA). Blood 2009; 113: 1294–1303.
Kay NE, Eckel-Passow JE, Braggio E, Vanwier S, Shanafelt TD, Van Dyke DL et al. Accelerating but ahead basic CLL patients with greater arrangement CGH complication display a beneath abiding acknowledgment to chemoimmunotherapy. Blight Genet Cytogenet 2010; 203: 161–168.
Saddler C, Ouillette P, Kujawski L, Shangary S, Talpaz M, Kaminski M et al. Absolute biomarker and genomic assay identifies p53 cachet as the above account of acknowledgment to MDM2 inhibitors in abiding lymphocytic leukemia. Blood 2008; 111: 1584–1593.
Ouillette P, Erba H, Kujawski L, Kaminski M, Shedden K, Malek SN. Integrated genomic profiling of abiding lymphocytic leukemia identifies subtypes of abatement 13q14. Blight Res 2008; 68: 1012–1021.
Kujawski L, Ouillette P, Erba H, Saddler C, Jakubowiak A, Kaminski M et al. Genomic complication identifies patients with advancing abiding lymphocytic leukemia. Blood 2008; 112: 1993–2003.
Haferlach C, Dicker F, Schnittger S, Kern W, Haferlach T. Absolute abiogenetic assuming of CLL: a abstraction on 506 cases analysed with chromosome amalgamation analysis, interphase FISH, IgV(H) cachet and immunophenotyping. Leukemia 2007; 21: 2442–2451.
Ouillette P, Fossum S, Parkin B, Ding L, Bockenstedt P, Al-Zoubi A et al. Advancing abiding lymphocytic leukemia with animated genomic complication is associated with assorted gene defects in the acknowledgment to DNA double-strand breaks. Clin Blight Res 2010; 16: 835–847.
Britt-Compton B, Lin TT, Ahmed G, Weston V, Jones RE, Fegan C et al. Extreme telomere abrasion in ATM-mutated and 11q-deleted CLL patients is absolute of ache stage. Leukemia 2012; 26: 826–830.
Augereau A, T’Kint de Roodenbeke C, Simonet T, Bauwens S, Horard B, Callanan M et al. Telomeric accident in aboriginal date of abiding lymphocytic leukemia correlates with shelterin dysregulation. Blood 2011; 118: 1316–1322.
Lin TT, Letsolo BT, Jones RE, Rowson J, Pratt G, Hewamana S et al. Telomere dysfunction and admixture during the progression of abiding lymphocytic leukemia: affirmation for a telomere crisis. Blood 2010; 116: 1899–1907.
Brugat T, Nguyen-Khac F, Grelier A, Merle-Beral H, Delic J. Telomere dysfunction-induced foci appear with the access of telomeric deletions and circuitous chromosomal aberrations in aggressive abiding lymphocytic leukemia cells. Blood 2010; 116: 239–249.
Roos G, Krober A, Grabowski P, Kienle D, Buhler A, Dohner H et al. Abbreviate telomeres are associated with abiogenetic complexity, high-risk genomic aberrations, and abbreviate adaptation in abiding lymphocytic leukemia. Blood 2008; 111: 2246–2252.
Bullrich F, Veronese ML, Kitada S, Jurlander J, Caligiuri MA, Reed JC et al. Minimal arena of accident at 13q14 in B-cell abiding lymphocytic leukemia. Blood 1996; 88: 3109–3115.
Liu Y, Hermanson M, Grander D, Merup M, Wu X, Heyman M et al. 13q deletions in lymphoid malignancies. Blood 1995; 86: 1911–1915.
Kalachikov S, Migliazza A, Cayanis E, Fracchiolla NS, Bonaldo MF, Lawton L et al. Cloning and gene mapping of the chromosome 13q14 arena deleted in abiding lymphocytic leukemia. Genomics 1997; 42: 369–377.
Kitamura E, Su G, Sossey-Alaoui K, Malaj E, Lewis J, Pan HQ et al. A archetype map of the minimally deleted arena from 13q14 in B-cell abiding lymphocytic leukemia as authentic by ample calibration sequencing of the 650 kb analytical region. Oncogene 2000; 19: 5772–5780.
Kapanadze B, Makeeva N, Corcoran M, Jareborg N, Hammarsund M, Baranova A et al. Comparative arrangement assay of a arena on animal chromosome 13q14, frequently deleted in B-cell abiding lymphocytic leukemia, and its akin arena on abrasion chromosome 14. Genomics 2000; 70: 327–334.
Migliazza A, Bosch F, Komatsu H, Cayanis E, Martinotti S, Toniato E et al. Nucleotide sequence, archetype map, and alteration assay of the 13q14 chromosomal arena deleted in B-cell abiding lymphocytic leukemia. Blood 2001; 97: 2098–2104.
Mabuchi H, Fujii H, Calin G, Alder H, Negrini M, Rassenti L et al. Cloning and assuming of CLLD6, CLLD7, and CLLD8, aberant applicant genes for leukemogenesis at chromosome 13q14, a arena frequently deleted in B-cell abiding lymphocytic leukemia. Blight Res 2001; 61: 2870–2877.
Ouillette P, Collins R, Shakhan S, Li J, Li C, Shedden K et al. The anxiety acceptation of assorted 13q14 deletions in abiding lymphocytic leukemia. Clin Blight Res 2011; 17: 6778–6790.
Mosca L, Fabris S, Lionetti M, Todoerti K, Agnelli L, Morabito F et al. Integrative genomics analyses acknowledge molecularly audible subgroups of B-cell abiding lymphocytic leukemia patients with 13q14 deletion. Clin Blight Res 2010; 16: 5641–5653.
Parker H, Rose-Zerilli MJ, Parker A, Chaplin T, Wade R, Gardiner A et al. 13q abatement assay and ache progression in patients with abiding lymphocytic leukemia. Leukemia 2011; 25: 489–497.
Fazi C, Scarfo L, Pecciarini L, Cottini F, Dagklis A, Janus A et al. General citizenry low-count CLL-like MBL persists over time afterwards analytic progression, although accustomed the aforementioned cytogenetic abnormalities of CLL. Blood 2011; 118: 6618–6625.
Lanasa MC, Allgood SD, Slager SL, Dave SS, Love C, Marti GE et al. Immunophenotypic and gene announcement assay of monoclonal B-cell lymphocytosis shows biologic characteristics associated with acceptable cast CLL. Leukemia 2011; 25: 1459–1466.
Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in abiding lymphocytic leukemia. Proc Natl Acad Sci USA 2002; 99: 15524–15529.
Sampath D, Liu C, Vasan K, Sulda M, Puduvalli VK, Wierda WG et al. Histone deacetylases arbitrate the silencing of miR-15a, miR-16 and miR-29b in abiding lymphocytic leukemia. Blood 2012; 119: 1162–1172.
Klein U, Lia M, Crespo M, Siegel R, Shen Q, Mo T et al. The DLEU2/miR-15a/16-1 array controls B corpuscle admeasurement and its abatement leads to abiding lymphocytic leukemia. Blight corpuscle 2010; 17: 28–40.
Lia M, Carette A, Tang H, Shen Q, Mo T, Bhagat G et al. Anatomic anatomization of the chromosome 13q14 tumor-suppressor locus application transgenic abrasion lines. Blood 2012; 119: 2981–2990.
Raveche ES, Salerno E, Scaglione BJ, Manohar V, Abbasi F, Lin YC et al. Abnormal microRNA-16 locus with synteny to animal 13q14 affiliated to CLL in NZB mice. Blood 2007; 109: 5079–5086.
Hammarsund M, Corcoran MM, Wilson W, Zhu C, Einhorn S, Sangfelt O et al. Assuming of a aberant B-CLL applicant gene–DLEU7–located in the 13q14 bump suppressor locus. FEBS Lett 2004; 556: 75–80.
Brown JR, Hanna M, Tesar B, Pochet N, Vartanov A, Fernandes SM et al. Germline archetype cardinal abnormality associated with Mendelian bequest of CLL in two families. Leukemia 2012; 26: 1710–1713.
Palamarchuk A, Efanov A, Nazaryan N, Santanam U, Alder H, Rassenti L et al. 13q14 deletions in CLL absorb allied bump suppressors. Blood 2010; 115: 3916–3922.
Dal Bo M, Rossi FM, Rossi D, Deambrogi C, Bertoni F, Del Giudice I et al. 13q14 abatement admeasurement and cardinal of deleted beef both access cast in abiding lymphocytic leukemia. Genes Chromosomes Blight 2011; 50: 633–643.
Liu Y, Szekely L, Grander D, Soderhall S, Juliusson G, Gahrton G et al. Abiding lymphocytic leukemia beef with allelic deletions at 13q14 frequently accept one complete RB1 gene: affirmation for a role of an adjoining locus. Proc Natl Acad Sci USA 1993; 90: 8697–8701.
Stilgenbauer S, Dohner H, Bulgay-Morschel M, Weitz S, Bentz M, Lichter P. High abundance of monoallelic retinoblastoma gene abatement in B-cell abiding lymphoid leukemia apparent by interphase cytogenetics. Blood 1993; 81: 2118–2124.
Shanafelt TD, Witzig TE, Fink SR, Jenkins RB, Paternoster SF, Smoley SA et al. -to-be appraisal of clonal change during abiding aftereffect of patients with basic early-stage abiding lymphocytic leukemia. J Clin Oncol 2006; 24: 4634–4641.
Malcikova J, Smardova J, Rocnova L, Tichy B, Kuglik P, Vranova V et al. Monoallelic and biallelic inactivation of TP53 gene in abiding lymphocytic leukemia: selection, appulse on adaptation and acknowledgment to DNA damage. Blood 2009; 114: 5307–5314.
Zenz T, Habe S, Denzel T, Mohr J, Winkler D, Buhler A et al. Abundant assay of p53 alleyway defects in fludarabine-refractory abiding lymphocytic leukemia (CLL): analytic the addition of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a -to-be analytic trial. Blood 2009; 114: 2589–2597.
Rossi D, Cerri M, Deambrogi C, Sozzi E, Cresta S, Rasi S et al. The anxiety amount of TP53 mutations in abiding lymphocytic leukemia is absolute of Del17p13: implications for all-embracing adaptation and chemorefractoriness. Clin Blight Res 2009; 15: 995–1004.
Dohner H, Fischer K, Bentz M, Hansen K, Benner A, Cabot G et al. p53 gene abatement predicts for poor adaptation and non-response to assay with purine analogs in abiding B-cell leukemias. Blood 1995; 85: 1580–1589.
Zenz T, Krober A, Scherer K, Habe S, Buhler A, Benner A et al. Monoallelic TP53 inactivation is associated with poor cast in abiding lymphocytic leukemia: after-effects from a abundant abiogenetic assuming with abiding follow-up. Blood 2008; 112: 3322–3329.
Dicker F, Herholz H, Schnittger S, Nakao A, Patten N, Wu L et al. The apprehension of TP53 mutations in abiding lymphocytic leukemia apart predicts accelerated ache progression and is awful activated with a circuitous abnormal karyotype. Leukemia 2009; 23: 117–124.
Rosenwald A, Chuang EY, Davis RE, Wiestner A, Alizadeh AA, Arthur DC et al. Fludarabine assay of patients with abiding lymphocytic leukemia induces a p53-dependent gene announcement response. Blood 2004; 104: 1428–1434.
Tam CS, Shanafelt TD, Wierda WG, Abruzzo LV, Van Dyke DL, O’Brien S et al. De novo abatement 17p13.1 abiding lymphocytic leukemia shows cogent analytic heterogeneity: the M. D. Anderson and Mayo Clinic experience. Blood 2009; 114: 957–964.
Best OG, Gardiner AC, Davis ZA, Tracy I, Ibbotson RE, Majid A et al. A subset of Binet date A CLL patients with TP53 abnormalities and mutated IGHV genes accept abiding disease. Leukemia 2009; 23: 212–214.
Knight SJ, Yau C, Clifford R, Timbs AT, Sadighi Akha E, Dreau HM et al. Quantification of subclonal distributions of alternate genomic aberrations in commutual pre-treatment and backsliding samples from patients with B-cell abiding lymphocytic leukemia. Leukemia 2012; 26: 1564–1575.
Braggio E, Kay NE, Vanwier S, Tschumper RC, Smoley S, Eckel-Passow JE et al. Longitudinal genome-wide assay of patients with abiding lymphocytic leukemia reveals circuitous change of clonal architectonics at ache progression and at the time of relapse. Leukemia 2012; 26: 1698–1701.
Stilgenbauer S, Sander S, Bullinger L, Benner A, Leupolt E, Winkler D et al. Clonal change in abiding lymphocytic leukemia: accretion of high-risk genomic aberrations associated with unmutated VH, attrition to therapy, and abbreviate survival. Haematologica 2007; 92: 1242–1245.
Rossi S, Shimizu M, Barbarotto E, Nicoloso MS, Dimitri F, Sampath D et al. microRNA fingerprinting of CLL patients with chromosome 17p abatement analyze a miR-21 account that stratifies aboriginal survival. Blood 2010; 116: 945–952.
Fegan C, Robinson H, Thompson P, Whittaker JA, White D. Karyotypic change in CLL: identification of a new sub-group of patients with deletions of 11q and avant-garde or accelerating disease. Leukemia 1995; 9: 2003–2008.
Neilson JR, Auer R, White D, Bienz N, Waters JJ, Whittaker JA et al. Deletions at 11q analyze a subset of patients with archetypal CLL who appearance constant ache progression and bargain survival. Leukemia 1997; 11: 1929–1932.
Saiya-Cork K, Collins R, Parkin B, Ouillette P, Kuizon E, Kujawski L et al. A pathobiological role of the insulin receptor in abiding lymphocytic leukemia. Clin Blight Res 2011; 17: 2679–2692.
Rossi D, Fangazio M, Rasi S, Vaisitti T, Monti S, Cresta S et al. Disruption of BIRC3 assembly with fludarabine chemorefractoriness in TP53 wild-type abiding lymphocytic leukemia. Blood 2012; 119: 2854–2862.
Mohr J, Helfrich H, Fuge M, Eldering E, Buhler A, Winkler D et al. DNA damage-induced transcriptional affairs in CLL: biological and analytic implications for anatomic p53 testing. Blood 2011; 117: 1622–1632.
Herling M, Patel KA, Weit N, Lilienthal N, Hallek M, Keating MJ et al. High TCL1 levels are a brand of B-cell receptor alleyway admiration and adverse aftereffect in abiding lymphocytic leukemia. Blood 2009; 114: 4675–4686.
Tsimberidou AM, Tam C, Abruzzo LV, O’Brien S, Wierda WG, Lerner S et al. Chemoimmunotherapy may affected the adverse anxiety acceptation of 11q abatement in ahead basic patients with abiding lymphocytic leukemia. Blight 2009; 115: 373–380.
Dohner H, Stilgenbauer S, James MR, Benner A, Weilguni T, Bentz M et al. 11q deletions analyze a new subset of B-cell abiding lymphocytic leukemia characterized by all-encompassing nodal captivation and inferior prognosis. Blood 1997; 89: 2516–2522.
Shedden K, Li Y, Ouillette P, Malek SN. Characteristics of abiding lymphocytic leukemia with somatically acquired mutations in NOTCH1 exon 34. Leukemia 2012; 26: 1108–1110.
Balatti V, Bottoni A, Palamarchuk A, Alder H, Rassenti LZ, Kipps TJ et al. NOTCH1 mutations in CLL associated with trisomy 12. Blood 2012; 119: 329–331.
Lopez C, Delgado J, Costa D, Conde L, Ghita G, Villamor N et al. Altered administration of NOTCH1 mutations in abiding lymphocytic leukemia with abandoned trisomy 12 or associated with added chromosomal alterations. Genes Chromosomes Blight 2012; 51: 881–889.
Del Giudice I, Rossi D, Chiaretti S, Marinelli M, Tavolaro S, Gabrielli S et al. NOTCH1 mutations in 12 abiding lymphocytic leukemia (CLL) advise an abortive prognosis, abet a characteristic transcriptional profiling and clarify the average cast of 12 CLL. Haematologica 2012; 97: 437–441.
Decker S, Zirlik K, Djebatchie L, Hartmann D, Ihorst G, Schmitt-Graeff A et al. Trisomy 12 and animated GLI1 and PTCH1 archetype levels are biomarkers for Hedgehog-inhibitor admiration in CLL. Blood 2012; 119: 997–1007.
Zenz T, Vollmer D, Trbusek M, Smardova J, Benner A, Soussi T et al. TP53 alteration contour in abiding lymphocytic leukemia: affirmation for a ache specific contour from a absolute assay of 268 mutations. Leukemia 2010; 24: 2072–2079.
Puente XS, Pinyol M, Quesada V, Conde L, Ordonez GR, Villamor N et al. Whole-genome sequencing identifies alternate mutations in abiding lymphocytic leukaemia. Nature 2011; 475: 101–105.
Fabbri G, Rasi S, Rossi D, Trifonov V, Khiabanian H, Ma J et al. Assay of the abiding lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med 2011; 208: 1389–1401.
Trbusek M, Smardova J, Malcikova J, Sebejova L, Dobes P, Svitakova M et al. Missense mutations amid in structural p53 DNA-binding motifs are associated with acutely poor adaptation in abiding lymphocytic leukemia. J Clin Oncol 2011; 29: 2703–2708.
Gaidano G, Ballerini P, Gong JZ, Inghirami G, Neri A, Newcomb EW et al. p53 mutations in animal lymphoid malignancies: affiliation with Burkitt lymphoma and abiding lymphocytic leukemia. Proc Natl Acad Sci USA 1991; 88: 5413–5417.
Zainuddin N, Murray F, Kanduri M, Gunnarsson R, Smedby KE, Enblad G et al. TP53 mutations are exceptional in anew diagnosed abiding lymphocytic leukemia. Leuk Res 2011; 35: 272–274.
Johnson GG, Sherrington PD, Carter A, Lin K, Liloglou T, Field JK et al. A aberant blazon of p53 alleyway dysfunction in abiding lymphocytic leukemia constant from two interacting distinct nucleotide polymorphisms aural the p21 gene. Blight Res 2009; 69: 5210–5217.
el Rouby S, Thomas A, Costin D, Rosenberg CR, Potmesil M, Silber R et al. p53 gene alteration in B-cell abiding lymphocytic leukemia is associated with biologic attrition and is absolute of MDR1/MDR3 gene expression. Blood 1993; 82: 3452–3459.
Wattel E, Preudhomme C, Hecquet B, Vanrumbeke M, Quesnel B, Dervite I et al. p53 mutations are associated with attrition to chemotherapy and abbreviate adaptation in hematologic malignancies. Blood 1994; 84: 3148–3157.
Gonzalez D, Martinez P, Wade R, Hockley S, Oscier D, Matutes E et al. Mutational cachet of the TP53 gene as a augur of acknowledgment and adaptation in patients with abiding lymphocytic leukemia: after-effects from the LRF CLL4 trial. J Clin Oncol 2011; 29: 2223–2229.
Zenz T, Eichhorst B, Busch R, Denzel T, Habe S, Winkler D et al. TP53 alteration and adaptation in abiding lymphocytic leukemia. J Clin Oncol 2010; 28: 4473–4479.
Sorror ML, Storer BE, Sandmaier BM, Maris M, Shizuru J, Maziarz R et al. Five-year aftereffect of patients with avant-garde abiding lymphocytic leukemia advised with allogeneic hematopoietic corpuscle transplantation afterwards nonmyeloablative conditioning. J Clin Oncol 2008; 26: 4912–4920.
Malek S. Analytic account of anxiety markers in abiding lymphocytic leukemia. ASCO Education Book 2010 [review]263–267.
Bullrich F, Rasio D, Kitada S, Starostik P, Kipps T, Keating M et al. ATM mutations in B-cell abiding lymphocytic leukemia. Blight Res 1999; 59: 24–27.
Schaffner C, Stilgenbauer S, Rappold GA, Dohner H, Lichter P. Somatic ATM mutations announce a pathogenic role of ATM in B-cell abiding lymphocytic leukemia. Blood 1999; 94: 748–753.
Stankovic T, Weber P, Stewart G, Bedenham T, Murray J, Byrd PJ et al. Inactivation of anarchy telangiectasia mutated gene in B-cell abiding lymphocytic leukaemia. Lancet 1999; 353: 26–29.
Austen B, Skowronska A, Baker C, Powell JE, Gardiner A, Oscier D et al. Alteration cachet of the balance ATM allele is an important account of the cellular acknowledgment to chemotherapy and adaptation in patients with abiding lymphocytic leukemia absolute an 11q deletion. J Clin Oncol 2007; 25: 5448–5457.
Ouillette P, Li J, Shaknovich R, Li Y, Melnick A, Shedden K et al. Incidence and analytic implications of ATM aberrations in abiding lymphocytic leukemia. Genes Chromosomes Blight 2012, (in press).
Austen B, Powell JE, Alvi A, Edwards I, Hooper L, Starczynski J et al. Mutations in the ATM gene advance to broken all-embracing and treatment-free adaptation that is absolute of IGVH alteration cachet in patients with B-CLL. Blood 2005; 106: 3175–3182.
Cejkova S, Rocnova L, Potesil D, Smardova J, Novakova V, Chumchalova J et al. Presence of heterozygous ATM abatement may not be analytical in the primary acknowledgment of abiding lymphocytic leukemia beef to fludarabine. Eur J Haematol 2009; 82: 133–142.
Lozanski G, Ruppert AS, Heerem NA, Lozanski A, Luca DM, Gordon A et al. Variations of the ATM gene in abiding lymphocytic leukemia patients abridgement abundant appulse on progression-free adaptation and all-embracing survival: a Blight and Leukemia Group B Study. Leuk Lymphoma 2012; 53: 1743–1748.
Balatti V, Bottoni A, Palamarchuk A, Alder H, Rassenti LZ, Kipps TJ et al. NOTCH1 mutations in CLL associated with trisomy 12. Blood 2012; 119: 329–331.
Rossi D, Rasi S, Fabbri G, Spina V, Fangazio M, Forconi F et al. Mutations of NOTCH1 are an absolute augur of adaptation in abiding lymphocytic leukemia. Blood 2012; 119: 521–529.
Rossi D, Bruscaggin A, Spina V, Rasi S, Khiabanian H, Messina M et al. Mutations of the SF3B1 splicing agency in abiding lymphocytic leukemia: affiliation with progression and fludarabine-refractoriness. Blood 2011; 118: 6904–6908.
Brown JR, Levine RL, Thompson C, Basile G, Gilliland DG, Freedman AS. Systematic genomic awning for tyrosine kinase mutations in CLL. Leukemia 2008; 22: 1966–1969.
Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim KH et al. Oncogenically alive MYD88 mutations in animal lymphoma. Nature 2011; 470: 115–119.
Gahrton G, Robert KH, Friberg K, Zech L, Bird AG. Nonrandom chromosomal aberrations in abiding lymphocytic leukemia appear by polyclonal B-cell-mitogen stimulation. Blood 1980; 56: 640–647.
Juliusson G, Oscier DG, Fitchett M, Ross FM, Stockdill G, Mackie MJ et al. Anxiety subgroups in B-cell abiding lymphocytic leukemia authentic by specific chromosomal abnormalities. N Engl J Med 1990; 323: 720–724.
Peterson LC, Lindquist LL, Church S, Kay NE. Frequent clonal abnormalities of chromosome bandage 13q14 in B-cell abiding lymphocytic leukemia: assorted clones, subclones, and nonclonal alterations in 82 midwestern patients. Genes Chromosomes Blight 1992; 4: 273–280.
Dohner H, Stilgenbauer S, Fischer K, Bentz M, Lichter P. Cytogenetic and atomic cytogenetic assay of B corpuscle abiding lymphocytic leukemia: specific chromosome aberrations analyze anxiety subgroups of patients and point to loci of applicant genes. Leukemia 1997; 11: S19–S24.
Dicker F, Schnittger S, Haferlach T, Kern W, Schoch C. Immunostimulatory oligonucleotide-induced metaphase cytogenetics ascertain chromosomal aberrations in 80% of CLL patients: A abstraction of 132 CLL cases with alternation to FISH, IgVH status, and CD38 expression. Blood 2006; 108: 3152–3160.
Put N, Konings P, Rack K, Jamar M, Van Roy N, Libouton JM et al. Improved apprehension of chromosomal abnormalities in abiding lymphocytic leukemia by accepted cytogenetics application CpG oligonucleotide and interleukin-2 stimulation: a Belgian multicentric study. Genes Chromosomes Blight 2009; 48: 843–853.
Mayr C, Speicher MR, Kofler DM, Buhmann R, Strehl J, Busch R et al. Chromosomal translocations are associated with poor cast in abiding lymphocytic leukemia. Blood 2006; 107: 742–751.
Heerema NA, Byrd JC, Dal Cin PS, Dell’ Aquila ML, Koduru PR, Aviram A et al. Dispatch of abiding lymphocytic leukemia beef with CpG oligodeoxynucleotide gives constant karyotypic after-effects amid laboratories: a CLL Research Consortium (CRC) Study. Blight Genet Cytogenet 2010; 203: 134–140.
Muthusamy N, Breidenbach H, Andritsos L, Flynn J, Jones J, Ramanunni A et al. Enhanced apprehension of chromosomal abnormalities in abiding lymphocytic leukemia by accepted cytogenetics application CpG oligonucleotide in aggregate with pokeweed mitogen and phor myristate acetate. Blight Genet 2011; 204: 77–83.
Huh YO, Schweighofer CD, Ketterling RP, Knudson RA, Vega F, Kim JE et al. Abiding lymphocytic leukemia with t(14;19)(q32;q13) is characterized by aberant morphologic and immunophenotypic appearance and characteristic abiogenetic features. Am J Clin Pathol 2011; 135: 686–696.
Martin-Subero JI, Ibbotson R, Klapper W, Michaux L, Callet-Bauchu E, Berger F et al. A absolute abiogenetic and histopathologic assay identifies two subgroups of B-cell malignancies accustomed a t(14;19)(q32;q13) or alternative BCL3-translocation. Leukemia 2007; 21: 1532–1544.
Ueshima Y, Bird ML, Vardiman JW, Rowley JDA. 14;19 about-face in B-cell abiding lymphocytic leukemia: a new alternating chromosome aberration. Int J Blight 1985; 36: 287–290.
Nguyen-Khac F, Chapiro E, Lesty C, Grelier A, Luquet I, Radford-Weiss I et al. Specific chromosomal IG translocations accept altered prognoses in abiding lymphocytic leukemia. Am J Blood Res 2011; 1: 13–21.
Van Den Neste E, Robin V, Francart J, Hagemeijer A, Stul M, Vandenberghe P et al. Chromosomal translocations apart adumbrate assay failure, treatment-free adaptation and all-embracing adaptation in B-cell abiding lymphocytic leukemia patients advised with cladribine. Leukemia 2007; 21: 1715–1722.
Rigolin GM, Cibien F, Martinelli S, Formigaro L, Rizzotto L, Tammiso E et al. Chromosome aberrations detected by accepted karyotyping application aberant mitogens in abiding lymphocytic leukemia with ‘normal’ FISH: correlations with clinicobiologic parameters. Blood 2012; 119: 2310–2313.
Visone R, Rassenti LZ, Veronese A, Taccioli C, Costinean S, Aguda BD et al. Karyotype-specific microRNA signature in abiding lymphocytic leukemia. Blood 2009; 114: 3872–3879.
Kanduri M, Cahill N, Göransson H, Enström C, Ryan F, Isaksson A et al. Differential genome-wide array-based methylation profiles in anxiety subsets of abiding lymphocytic leukemia. Blood 2010; 115: 296–305.
Herman SE, Gordon AL, Hertlein E, Ramanunni A, Zhang X, Jaglowski S et al. Bruton tyrosine kinase represents a able ameliorative ambition for assay of abiding lymphocytic leukemia and is finer targeted by PCI-32765. Blood 2011; 117: 6287–6296.
Hoellenriegel J, Meadows SA, Sivina M, Wierda WG, Kantarjian H, Keating MJ et al. The phosphoinositide 3′-kinase basin inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in abiding lymphocytic leukemia. Blood 2011; 118: 3603–3612.
Ponader S, Chen SS, Buggy JJ, Balakrishnan K, Gandhi V, Wierda WG et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts abiding lymphocytic leukemia corpuscle adaptation and tissue homing in vitro and in vivo. Blood 2012; 119: 1182–1189.
The Five Reasons Tourists Love Rp 9 Form Download | Rp 9 Form Download – rp 5217 form download
| Pleasant for you to my personal blog, with this period I’m going to teach you about rp 5217 form download